Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1139-1155

  Mizokami, Atsushi ^a   Koh, Eitetsu ^a   Izumi, Kouji ^a   Narimoto, Kazutaka ^a   Takeda, Masashi ^a   Honma, Seijiro ^b   Dai, Jinlu ^c   Keller, Evan T ^c   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b Grelan Pharmaceutical Co Ltd   (Japan)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; DUTASTERIDE; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADRENAL GLAND; ADULT; ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; CELL STRAIN LNCAP; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROSTATE CANCER; STROMA CELL; TESTOSTERONE SYNTHESIS;

BLOTTING, WESTERN; BONE AND BONES; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; COCULTURE TECHNIQUES; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; HUMANS; LUCIFERASES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STROMAL CELLS; TESTOSTERONE; TRANSFECTION;

EID: 72549095373     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0070     Document Type: Article

References (45)

1. Akaza H 2007 Global update on defining and treating highrisk localized prostate cancer with leuprorelin: a Japanese perspective - the effect of primary androgen deprivation therapy on stage C prostate cancer. BJU International 99 10-12 (discussion 17-18). (Pubitemid 44952821)
2. Andersson S & Russell DW 1990 Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. PNAS 87 3640-3644. (Pubitemid 20182514)
3. Andersson S, Berman DM, Jenkins EP & Russell DW 1991 Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354 159-161. (Pubitemid 21896802)
4. Arnold JT, Le H, McFann KK & Blackman MR 2005 Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. American Journal of Physiology 288 E573-E584.
5. Arnold JT, Gray NE, Jacobowitz K, Viswanathan L, Cheung PW, McFann KK, Le H & Blackman MR 2008 Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. Journal of Steroid Biochemistry and Molecular Biology 111 240-246.
6. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E et al. 2008 Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology 26 4563-4571.
7. Belanger B, Belanger A, Labrie F, Dupont A, Cusan L & Monfette G 1989 Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. Journal of Steroid Biochemistry 32 695-698. (Pubitemid 19176012)
8. Cano P, Godoy A, Escamilla R, Dhir R & Onate SA 2007 Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cancer Research 67 511-519. (Pubitemid 46192187)
9. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (Pubitemid 38524696)
10. Cunha GR, Cooke PS & Kurita T 2004 Role of stromal-epithelial interactions in hormonal responses. Archives of Histology and Cytology 67 417-434. (Pubitemid 40424552)
11. Dufort I, Rheault P, Huang XF, Soucy P & Luu-The V 1999 Characteristics of a highly labile human type 5 17b-hydroxysteroid dehydrogenase. Endocrinology 140 568-574. (Pubitemid 29058186)
12. Feldman BJ & Feldman D 2001 The development of androgen-independent prostate cancer. Nature Reviews. Cancer 1 34-45.
13. Forti G, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marinoni T, Natali A, Costantini A, Serio M, Martini L et al. 1989 Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5α-reductase activity and androgen receptor content. Journal of Clinical Endocrinology and Metabolism 68 461-468. (Pubitemid 19052893)
14. Fujimoto N, Mizokami A, Harada S & Matsumoto T 2001 Different expression of androgen receptor coactivators in human prostate. Urology 58 289-294. (Pubitemid 32728083)
15. Fung KM, Samara EN, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JV, Culkin DJ et al. 2006 Increased expression of type 2 3α-hydroxysteroid dehydrogenase/ type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocrine-Related Cancer 13 169-180.
16. Geissler WM, Davis DL, Wu L, Bradshaw KD, Patel S, Mendonca BB, Elliston KO, Wilson JD, Russell DW & Andersson S 1994 Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3. Nature Genetics 7 34-39. (Pubitemid 24977991)
17. Gobec S, Brozic P & Rizner TL 2005 Nonsteroidal antiinflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents. Bioorganic and Medicinal Chemistry Letters 15 5170-5175. (Pubitemid 41463641)
18. Harada S, Keller ET, Fujimoto N, Koshida K, Namiki M, Matsumoto T & Mizokami A 2001 Long-term exposure of tumor necrosis factor α causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate 46 319-326. (Pubitemid 32186915)
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T & Thun MJ 2008 Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 58 71-96.
20. Kaminski A, Hahne JC, Haddouti el-M, Florin A, Wellmann A & Wernert N 2006 Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts. International Journal of Molecular Medicine 18 941-950.
21. Krill D, Shuman M, Thompson MT, Becich MJ & Strom SC 1997 A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates. Urology 49 981-988. (Pubitemid 27246978)
22. Labrie F 1991 Intracrinology. Molecular and Cellular Endocrinology 78 C113-C118.
23. Labrie F 2007 Multiple intracrine hormonal targets in the prostate: opportunities and challenges. BJU International 100 48-51. (Pubitemid 46985614)
24. Labrie F, Dupont A & Belanger A 1985 Complete androgen blockade for the treatment of prostate cancer. Important Advances in Oncology 193-217.
25. Labrie F, Belanger A, Dupont A, Luu-The V, Simard J & Labrie C 1993 Science behind total androgen blockade: from gene to combination therapy. Clinical and Investigative Medicine 16 475-492. (Pubitemid 24111962)
26. Labrie F, Luu-The V, Belanger A, Lin SX, Simard J, Pelletier G & Labrie C 2005 Is dehydroepiandrosterone a hormone? Journal of Endocrinology 187 169-196.
27. Lazier CB, Thomas LN, Douglas RC, Vessey JP & Rittmaster RS 2004 Dutasteride, the dual 5α-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 58 130-144.
28. Le H, Arnold JT, McFann KK & Blackman MR 2006 DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. American Journal of Physiology 290 E952-E960.
29. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z & Keller ET 2004 Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clinical and Experimental Metastasis 21 399-408.
30. Luu-The V, Belanger A & Labrie F 2008 Androgen biosynthetic pathways in the human prostate. Best Practice and Research. Clinical Endocrinology and Metabolism 22 207-221. (Pubitemid 351611954)
31. Mizokami A, Gotoh A, Yamada H, Keller ET & Matsumoto T 2000 Tumor necrosis factor-α represses androgen sensitivity in the LNCaP prostate cancer cell line. Journal of Urology 164 800-805. (Pubitemid 30637637)
32. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET & Namiki M 2004 The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Research 64 765-771. (Pubitemid 38120921)
33. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM & French FS 2004 The androgen axis in recurrent prostate cancer. Clinical Cancer Research 10 440-448. (Pubitemid 38173980)
34. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD & Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 68 4447-4454.
35. Nishiyama T, Hashimoto Y & Takahashi K 2004 The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clinical Cancer Research 10 7121-7126. (Pubitemid 39487695)
36. Pelletier G, Luu-The V, El-Alfy M, Li S & Labrie F 2001 Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. Journal of Molecular Endocrinology 26 11-19. (Pubitemid 32125118)
37. Schroder FH 2008 Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. European Urology 53 1129-1137.
38. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG & Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 66 2815-2825.
39. Sung SY & Chung LW 2002 Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation; Research in Biological Diversity 70 506-521.
40. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R & Shimazaki J 1996 Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77 934-940. (Pubitemid 26061289)
41. Taplin ME & Balk SP 2004 Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. Journal of Cellular Biochemistry 91 483-490.
42. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS & Tindall DJ 2008 Type 1 and type 2 5α-reductase expression in the development and progression of prostate cancer. European Urology 53 244-252. (Pubitemid 350296595)
43. Titus MA, Schell MJ, Lih FB, Tomer KB & Mohler JL 2005 Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 11 4653-4657.
44. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y & Nakagawa H 2008 Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormonerefractory prostate cancer. Cancer Science 99 81-86. (Pubitemid 350239034)
45. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO & Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochemical and Biophysical Research Communications 173 534-540.